AI Diagnostics provides an AI-powered platform that analyzes lung sounds using a digital stethoscope to improve tuberculosis screening accuracy. Its proprietary AI model identifies acoustic patterns indicative of pulmonary TB, offering a rapid and cost-effective screening solution that reduces missed diagnoses and unnecessary testing.
Funding
$22.7K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current tuberculosis (TB) screening methods, primarily symptom-based, miss approximately 29% of positive cases, allowing untreated individuals to spread the disease. Furthermore, the low accuracy of existing screening tools leads to significant expenditure on testing TB-negative patients, estimated at $1.3 billion globally in 2022.
Solution
AI Diagnostics offers an AI-powered lung sound analysis platform designed to improve the accuracy and efficiency of TB screening. The system utilizes a digital stethoscope to capture breath sounds from patients, which are then processed by a proprietary AI model. This model analyzes subtle acoustic patterns indicative of pulmonary TB, providing a rapid screening result. By identifying potential TB cases with higher sensitivity and specificity than traditional methods, AI Diagnostics aims to reduce missed diagnoses, decrease unnecessary testing, and lower overall healthcare costs associated with TB management. The platform is designed for offline operation, enhancing accessibility in diverse healthcare settings.
Target Audience
The primary target audience includes public health organizations, private healthcare providers, pharmacy clinics, correctional services, occupational health departments, emigration services, NGOs, and mining companies seeking to enhance their TB screening protocols.
Features
- Digital stethoscope for capturing lung sounds at six anatomical positions.
- AI model for analyzing acoustic data to identify patterns associated with pulmonary TB.
- Offline operational capability, eliminating the need for a constant internet connection.
- SAHPRA approval for use in South Africa.
- High sensitivity (90%) and specificity (68%) in TB screening.
- Cost-effective solution, with an average screening cost of $2 per patient.
- Compatibility with Windows 10 and 11 operating systems for offline analysis.
- Browser-based system development underway for Android and iOS.
- Ability to detect pulmonary TB, which accounts for 83% of global TB cases.
- Hardware is 100x more affordable than digital X-ray machines.